Immunomedics Inc

Find Ratings Reports
IMMU : NASDAQ : Health Care
$5.44 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 3999000.0
04/25/17 - 4:00 PM ET

Financial Analysis


IMMUNOMEDICS INC's gross profit margin for the second quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. IMMUNOMEDICS INC has strong liquidity. Currently, the Quick Ratio is 1.62 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

At the same time, stockholders' equity ("net worth") has significantly decreased by 138.35% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY17 Q2 FY16
Net Sales ($mil)0.380.67
EBITDA ($mil)-15.13-15.53
EBIT ($mil)-15.36-15.7
Net Income ($mil)-24.45-13.75


Balance Sheet Q2 FY17 Q2 FY16
Cash & Equiv. ($mil)46.6176.04
Total Assets ($mil)53.1281.96
Total Debt ($mil)97.7296.99
Equity ($mil)-74.44-31.23


Profitability Q2 FY17 Q2 FY16
Gross Profit Margin-3939.32-2314.46
EBITDA Margin-3939.32-2314.45
Operating Margin-4000.0-2339.49
Sales Turnover0.060.06
Return on Assets-132.78-65.02
Return on Equity0.00.0
Debt Q2 FY17 Q2 FY16
Current Ratio1.695.18
Debt/Capital4.21.47
Interest Expense1.721.37
Interest Coverage-8.95-11.46


Share Data Q2 FY17 Q2 FY16
Shares outstanding (mil)105.9994.71
Div / share0.00.0
EPS-0.23-0.15
Book value / share-0.7-0.33
Institutional Own % n/a n/a
Avg Daily Volume3884922.01865648.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
IMMU NM Peers 37.21   IMMU NM Peers 24.72

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

IMMU's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

IMMU's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
IMMU 398.67 Peers 43.15   IMMU NA Peers 0.49

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

IMMU's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
IMMU NM Peers 11.43   IMMU -26.31 Peers 149.25

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

IMMU's P/B is negative making this valuation measure meaningless.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, IMMU is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
IMMU 214.13 Peers 191.95   IMMU -40.63 Peers 395.13

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

IMMU is trading at a premium to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

IMMU significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades